XML 37 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
INTANGIBLE ASSETS (Tables)
 12 Months Ended
Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of December 31, 2014 and December 31, 2013:

  

   December 31, 2014
   Gross Carrying Amount  Accumulated Amortization  Net  
Amount		  Weighted- Average  
Remaining Amortization Period (yrs.)
Amortizing intangible assets:            
OPERA® software patent  $31,951   $(2,496)  $29,455    14.75 
Development costs of corporate website  91,743    (91,743)   —      n/a 
Approved hormone therapy drug candidate patents   439,184    (19,401)   419,783    18 
                     
Non-amortizing intangible assets:                    
Hormone therapy drug candidate patents (pending)   675,982    —      675,982    n/a 
Multiple trademarks for vitamins/supplements   103,368    —      103,368    n/a 
Total  $1,342,228   $(113,640)  $1,228,588      

 

   December 31, 2013
   Gross Carrying Amount  Accumulated Amortization  Net  
Amount		  Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:            
OPERA® software patent  $31,951   $(499)  $31,452    15.8 
Development costs of corporate website   91,743    (89,661)   2,082    0.3 
                     
Non-amortizing intangible assets:                    
Hormone therapy drug candidate patents (pending)   572,726    —      572,726    n/a 
Multiple trademarks for vitamins/supplements   59,328    —      59,328    n/a 
Total  $755,748   $(90,160)  $665,588      

 
Schedule of estimated amortization expense

As of December 31, 2014, the estimated amortization expense for the next five years is as follows:

 

Year Ending December 31,  Estimated Amortization
2015   $25,138 
2016   $25,138 
2017   $25,138 
2018   $25,138 
2019   $25,138